A review on cold agglutinin disease recaps how clonal B-cell biology and complement-driven hemolysis shape symptoms and treatment response, highlighting why steroids and splenectomy often fail. The article positions sutimlimab plus emerging agents as reshaping care, reflecting a shift toward complement-targeted approaches. For hematology stakeholders, the key signal is treatment modernization: therapies increasingly act upstream in the complement cascade rather than relying on broad immunosuppression. The review format means it summarizes evidence rather than reports new trial endpoints, but it can inform clinical strategy and development priorities for next-generation agents.